Skip to main content

Table 2 Univariate analysis of the infections in the MM patients

From: Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics

Factors Investigated cases
(n = 161)
Group with infections (%)
(n = 126)
Group without infections (%)
(n = 35)
χ2 P value
Sex     3.132 0.077
 Male 94 69 (73.4) 25 (26.6)   
 Female 67 57 (85.1) 10 (14.9)   
Age     2.583 0.108
 <60 51 36 (70.6) 15 (29.4)   
  ≥ 60 110 90 (81.8) 20 (18.2)   
ECOG score     4.294 0.038
  ≤ 2 100 73 (73.0) 27 (27.0)   
 >2 61 53 (86.9) 8 (13.1)   
Immunophenotype     0.672 0.880
 IgG 70 54 (77.1) 16 (22.9)   
 IgA 49 39 (79.6) 10 (20.4)   
 Light chain 32 26 (81.3) 6 (18.8)   
 Others 10 7 (70.0) 3 (30.0)   
Durie-Salmon stage     6.540 0.011
 Stage I-II 36 23 (63.9) 13 (36.1)   
 Stage III 122 102 (83.6) 20 (16.4)   
ISS stage     7.728 0.005
 Stage I-II 56 37 (66.1) 19 (33.9)   
 Stage III 101 86 (85.1) 15 (14.9)   
RBC (/L)     0.448 0.503
  < 3.8 × 1012(f); 153 121 (79.1) 32 (20.9)   
  < 4.3 × 1012(m)
≥3.8 × 1012(f); ≥4.3 × 1012(m)
8 5 (62.5) 3 (37.5)   
Haemoglobin (g/L)     6.092 0.014
 <90 98 83 (84.7) 15 (15.3)   
  ≥ 90 63 43 (68.3) 20 (31.7)   
ANC (/L)     0.000 1.000
 <1.5 × 109 19 15 (78.9) 4 (21.1)   
  ≥ 1.5 × 109 142 111 (78.2) 31 (21.8)   
ALC (/L)     3.676 0.055
  < 1.0 × 109 38 34 (89.5) 4 (10.5)   
  ≥ 1.0 × 109 123 92 (74.8) 31 (25.2)   
CRP (mg/L)     7.235 0.007
  ≤ 10 95 69 (72.6) 26 (27.4)   
 >10 62 56 (90.3) 6 (9.7)   
Albumin (g/L)     3.155 0.076
 <35 111 91 (82.0) 20 (18.0)   
  ≥ 35 49 34 (69.3) 15 (30.6)   
Globulin (g/L)     0.056 0.813
  ≤ 30 39 31 (79.5) 8 (20.5)   
 >30 121 94 (77.7) 27 (22.3)   
Serum creatinine (μmol/L)     0.450 0.502
 <177 117 90 (76.9) 27 (23.1)   
  ≥ 177 44 36 (81.8) 8 (18.2)   
Serum calcium (mmol/L)     0.651 0.420
  ≤ 2.75 149 115 (77.2) 34 (22.8)   
 >2.75 12 11 (91.7) 1 (8.3)   
β2-MG (mg/L)     1.805 0.179
 <5.5 69 51 (73.9) 18 (26.1)   
  ≥ 5.5 87 72 (82.8) 15 (17.2)   
LDH (U/L)     0.124 0.725
  ≤ 243 105 85 (81.0) 20 (19.0)   
 >243 32 25 (78.1) 7 (21.9)   
Bone destruction     3.581 0.058
 Yes 99 82 (82.8) 17 (17.2)   
 No 60 42 (70.0) 18 (30.0)   
Invasive operation     1.193 0.275
 Yes 138 110 (79.7) 28 (20.3)   
 No 23 16 (69.6) 7 (30.4)   
Renal dysfunction     1.213 0.271
 Yes 52 38 (30.2) 14 (40.0)   
 No 109 88 (69.8) 21 (60.0)   
Cardiac dysfunction     0.373 0.541
 Yes 31 23 (18.3) 8 (22.9)   
 No 130 103 (81.7) 27 (77.1)   
Hypertension     0.814 0.367
 Yes 63 47 (37.3) 16 (45.7)   
 No 98 79 (62.7) 19 (54.3)   
Diabetes     0.915 0.229
 Yes 24 17 (13.5) 7 (20.0)   
 No 137 109 (86.5) 28 (80.0)   
  1. ECOG Eastern Cooperative Oncology Group, ISS International Staging System, RBC Red Blood Cells, f female, m male, ANC Absolute Neutrophil Count, ALC Absolute Lymphocyte Count, CRP C-reactive protein, β2-MG β2-microglobulin, LDH lactate dehydrogenase
  2. Reference ranges of the laboratory values in our study: RBC 3.8 ~ 5.1 × 1012 (f), 4.3 ~ 5.8 × 1012/L(m); CRP ≤ 10 mg/L.